Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism
- PMID: 18998768
- PMCID: PMC2581623
- DOI: 10.1371/journal.pmed.0050219
Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism
Abstract
Background: Resistance to triazoles was recently reported in Aspergillus fumigatus isolates cultured from patients with invasive aspergillosis. The prevalence of azole resistance in A. fumigatus is unknown. We investigated the prevalence and spread of azole resistance using our culture collection that contained A. fumigatus isolates collected between 1994 and 2007.
Methods and findings: We investigated the prevalence of itraconazole (ITZ) resistance in 1,912 clinical A. fumigatus isolates collected from 1,219 patients in our University Medical Centre over a 14-y period. The spread of resistance was investigated by analyzing 147 A. fumigatus isolates from 101 patients, from 28 other medical centres in The Netherlands and 317 isolates from six other countries. The isolates were characterized using phenotypic and molecular methods. The electronic patient files were used to determine the underlying conditions of the patients and the presence of invasive aspergillosis. ITZ-resistant isolates were found in 32 of 1,219 patients. All cases were observed after 1999 with an annual prevalence of 1.7% to 6%. The ITZ-resistant isolates also showed elevated minimum inhibitory concentrations of voriconazole, ravuconazole, and posaconazole. A substitution of leucine 98 for histidine in the cyp51A gene, together with two copies of a 34-bp sequence in tandem in the gene promoter (TR/L98H), was found to be the dominant resistance mechanism. Microsatellite analysis indicated that the ITZ-resistant isolates were genetically distinct but clustered. The ITZ-sensitive isolates were not more likely to be responsible for invasive aspergillosis than the ITZ-resistant isolates. ITZ resistance was found in isolates from 13 patients (12.8%) from nine other medical centres in The Netherlands, of which 69% harboured the TR/L98H substitution, and in six isolates originating from four other countries.
Conclusions: Azole resistance has emerged in A. fumigatus and might be more prevalent than currently acknowledged. The presence of a dominant resistance mechanism in clinical isolates suggests that isolates with this mechanism are spreading in our environment.
Conflict of interest statement
Figures



Similar articles
-
Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles.Clin Infect Dis. 2013 Aug;57(4):513-20. doi: 10.1093/cid/cit320. Epub 2013 May 10. Clin Infect Dis. 2013. PMID: 23667263
-
High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR/L98H, in a French cohort of patients with cystic fibrosis.J Antimicrob Chemother. 2012 Aug;67(8):1870-3. doi: 10.1093/jac/dks160. Epub 2012 May 11. J Antimicrob Chemother. 2012. PMID: 22581906
-
[Azole resistance in Aspergillus fumigatus in the Netherlands--increase due to environmental fungicides?].Ned Tijdschr Geneeskd. 2012;156(25):A4458. Ned Tijdschr Geneeskd. 2012. PMID: 22748367 Review. Dutch.
-
First determination of azole resistance in Aspergillus fumigatus strains carrying the TR34/L98H mutations in Turkey.J Infect Chemother. 2015 Aug;21(8):581-6. doi: 10.1016/j.jiac.2015.04.012. Epub 2015 May 14. J Infect Chemother. 2015. PMID: 26048062
-
Azole resistance in Aspergillus fumigatus: a growing public health concern.Curr Opin Infect Dis. 2013 Dec;26(6):493-500. doi: 10.1097/QCO.0000000000000005. Curr Opin Infect Dis. 2013. PMID: 24126719 Review.
Cited by
-
Aspergillus fumigatus and aspergillosis: From basics to clinics.Stud Mycol. 2021 May 10;100:100115. doi: 10.1016/j.simyco.2021.100115. eCollection 2021 Sep. Stud Mycol. 2021. PMID: 34035866 Free PMC article. Review.
-
Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis.Antimicrob Agents Chemother. 2013 Apr;57(4):1866-71. doi: 10.1128/AAC.02226-12. Epub 2013 Feb 4. Antimicrob Agents Chemother. 2013. PMID: 23380732 Free PMC article.
-
Emerging Fungal Infections: New Patients, New Patterns, and New Pathogens.J Fungi (Basel). 2019 Jul 20;5(3):67. doi: 10.3390/jof5030067. J Fungi (Basel). 2019. PMID: 31330862 Free PMC article. Review.
-
Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11).BMC Med. 2009 Sep 8;7:44. doi: 10.1186/1741-7015-7-44. BMC Med. 2009. PMID: 19735580 Free PMC article. Clinical Trial.
-
Contributions of yap1 Mutation and Subsequent atrF Upregulation to Voriconazole Resistance in Aspergillus flavus.Antimicrob Agents Chemother. 2018 Oct 24;62(11):e01216-18. doi: 10.1128/AAC.01216-18. Print 2018 Nov. Antimicrob Agents Chemother. 2018. PMID: 30126960 Free PMC article.
References
-
- Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis. 2007;44:531–540. - PubMed
-
- Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408–415. - PubMed
-
- Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348–359. - PubMed
-
- Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335–347. - PubMed
-
- Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med. 2007;356:1481–1483. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical